The heart plays both roles. In chronic heart failure, myostatin behaves like a paradox: the failing heart muscle secretes more of it, and the skeletal muscle of the same patient gets the worst of the damage from the elevated circulating pool.
That asymmetry is the part that catches the field off guard. If you lower myostatin everywhere with a drug, you might rescue skeletal muscle. But you might also remove an important brake on cardiac stress responses. The heart and the limbs disagree about whether myostatin is a problem.
Myostatin and heart failure quick stats
- Population: Roughly 64 million people worldwide live with heart failure; cardiac cachexia affects 15-20% of advanced cases
- Serum myostatin in HFrEF vs HFpEF: Median ~1675 pg/mL vs ~884 pg/mL (p = 0.007) in one 2024 study
- Where the elevated myostatin comes from: Failing cardiac muscle itself secretes meaningful amounts in heart failure, on top of normal skeletal-muscle production
- Skeletal muscle effect: Drives the muscle wasting that defines cardiac cachexia and worsens prognosis
- Approved myostatin drug for heart failure: None for myostatin specifically; sotatercept (an activin trap) approved for PAH
- Major open question: Whether systemic myostatin blockade is safe in patients with reduced ejection fraction
Key takeaways
- Myostatin is elevated in chronic heart failure, particularly in patients with impaired ejection fraction (HFrEF and HFmrEF), and is at least partly produced by the failing heart itself.
- In skeletal muscle, that elevated myostatin pool accelerates the protein breakdown that produces cardiac cachexia — a strong predictor of mortality in heart failure.
- In cardiac muscle, the role is more protective and complex. Knockout studies suggest myostatin restrains pathological cardiac hypertrophy and helps preserve cardiac energy homeostasis, which is why complete blockade may be unsafe.
- Sotatercept (Winrevair), an ActRIIA-Fc activin trap originally developed for muscle, is the only drug in this molecular family to win a cardiology indication — and it works in pulmonary arterial hypertension, not as a muscle drug.
- For heart failure patients today, the evidence-based path remains guideline-directed medical therapy (ACE-I/ARNI, beta-blocker, MRA, SGLT2 inhibitor), cardiac rehab, and treatment of cachexia drivers — not myostatin blockade.
Why the heart secretes myostatin when it fails
A stress signal, not a muscle-growth gene. In healthy adult hearts, myostatin expression is low. The cardiac muscle does not behave like a skeletal muscle pumping out myostatin to restrain its own growth.
The pattern changes in pathological stress. Animal models of cardiac pressure overload (aortic constriction), volume overload, ischemic injury, and heart failure all show increased myocardial myostatin expression. The cardiomyocytes themselves start producing meaningful amounts and releasing it into circulation.
That release matters at two levels:
- Locally, myostatin restrains cardiomyocyte hypertrophy and may help limit pathological remodeling
- Systemically, the released myostatin reaches skeletal muscle, where it activates the catabolic pathways that produce cardiac cachexia
The 2015 Circulation Research paper by Heineke and colleagues was one of the first to crisply make this point: cardiac myostatin secretion is a major contributor to the elevated systemic myostatin pool in heart failure, and skeletal muscle is paying the price for a signal the heart is sending under stress.
What the human data actually shows
The pattern by heart-failure type. A 2024 PMC paper measured serum myostatin in chronic heart failure patients and stratified them by ejection fraction.
Key findings:
- HFrEF and HFmrEF (impaired systolic function): median ~1675 pg/mL
- HFpEF (preserved ejection fraction): median ~884.5 pg/mL
- The difference was statistically significant (p = 0.007)
The myostatin elevation correlated with several functional and nutritional measures:
| Correlation with myostatin | r value | p value |
|---|---|---|
| Skeletal muscle mass | 0.27 | 0.04 |
| Norton scale (functional status) | 0.35 | <0.01 |
| Instrumental ADL | 0.28 | 0.02 |
| Barthel index | 0.27 | 0.03 |
| LVEF (ejection fraction) | not significant | n/s |
The clinically important point: myostatin is high in patients with worse pump function, and it correlates with functional status (how well a patient can do activities of daily living) — but not directly with the LVEF number itself. The signal is more about the systemic biology of advanced heart failure than the cardiac output number.
Earlier work, including a 2010 review in the European Journal of Heart Failure, identified myostatin as "an overlooked player in heart failure" and reported correlations between elevated serum myostatin and mortality, rehospitalization, and worse 6-minute walk performance.
The cardiac cachexia loop
This is where myostatin becomes prognostically important. Cardiac cachexia is the muscle-and-fat wasting syndrome that affects 15-20% of advanced heart failure patients and roughly halves their median survival compared to non-cachectic peers of similar EF.
The drivers are familiar: chronic inflammation, neurohormonal activation (high renin-angiotensin, high sympathetic tone), reduced physical activity, anorexia, and gut congestion impairing nutrient absorption. Myostatin elevation rides on all of these.
The downstream pathway is well-mapped. Myostatin binds ActRIIB on skeletal muscle, phosphorylates Smad2/3, and activates the atrogenes atrogin-1 and MuRF1, which tag muscle proteins for proteasomal destruction. The same pathway runs in CKD, cancer cachexia, and disuse atrophy.
In heart failure patients, the loss often shows up as quadriceps weakness, decreased exercise tolerance, falls, and reduced ability to tolerate guideline-directed medical therapy doses. Patients who cannot tolerate beta-blockade or RAS inhibition because of low blood pressure or fatigue often have the worst muscle picture.
For the broader sarcopenia and aging side, see myostatin and sarcopenia and myostatin and aging.
Why blocking myostatin in heart failure is harder than it sounds
The cardiac protective signal you do not want to lose. Animal studies suggest myostatin does several useful things in pathological heart conditions:
- Restrains pathological cardiac hypertrophy. Cardiac-specific myostatin knockout mice can develop exaggerated hypertrophy in response to pressure overload. The myostatin signal seems to act as a brake.
- Preserves cardiac energy homeostasis. Myostatin signaling regulates fatty acid utilization and mitochondrial function in cardiomyocytes. Removing it entirely affects how the heart fuels itself under stress.
- Modulates fibrosis. Some animal models suggest myostatin influences cardiac fibrosis pathways in ways that could either help or harm depending on the context.
This is part of why the bimagrumab, ACE-031, and other ActRIIB-targeted programs have largely avoided heart failure as a primary indication. The skeletal-muscle benefit is real, but the cardiac signal is uncertain enough that no sponsor has been comfortable running a large heart-failure trial with one of these drugs.
The PAH pivot from sotatercept is the cleanest example of how the field has worked around this. Sotatercept (Winrevair) was developed from the same Acceleron family as ACE-031, but at much lower doses targeting pulmonary vascular remodeling rather than skeletal muscle growth. The careful dosing and indication choice avoid the cardiac muscle blockade question almost entirely. The full sotatercept story is in our sotatercept article.
The drug pipeline at the cardiac-myostatin intersection
The most relevant programs.
| Drug | Mechanism | Cardiac relevance |
|---|---|---|
| Sotatercept (Winrevair) | ActRIIA-Fc activin trap | Approved for PAH; not for skeletal muscle or heart failure |
| Luspatercept (Reblozyl) | Modified ActRIIB-Fc fusion | Approved for anemia; cardiac safety monitored |
| Bimagrumab | Anti-ActRIIA/B antibody | Obesity programs; cardiac monitoring required, mild blood pressure and lipid changes observed |
| ACE-031 | ActRIIB-Fc fusion | Discontinued in DMD partly for vascular side effects |
| Taldefgrobep alfa | Anti-myostatin adnectin | Obesity / muscle preservation programs; cardiac safety still being characterized |
| Apitegromab | Anti-latent myostatin antibody | Approved for SMA; cardiac data limited |
| Garetosmab | Anti-activin A antibody | FOP indication; cardiac safety not the primary concern |
None of these is being developed primarily for heart failure. The closest cardiology relevance is sotatercept in pulmonary hypertension, which is a different problem.
For broader context on the antibody class, see our anti-myostatin antibody overview and the myostatin inhibitor drug pipeline review.
What heart failure patients can actually do today
The evidence-based path, in order of strength.
- Guideline-directed medical therapy. ACE inhibitor or ARNI, beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor in HFrEF; SGLT2 inhibitor as a backbone in HFpEF. Each of these has independent mortality benefit, and several (especially ACE-I and ARNI) blunt the angiotensin II signal that contributes to muscle wasting.
- Cardiac rehabilitation. Structured exercise programs lower skeletal muscle myostatin, improve functional capacity, and reduce mortality in heart failure. Most cardiology centers run rehab programs for both HFrEF and HFpEF, and insurance often covers them.
- Resistance training as part of rehab. Light-to-moderate resistance training is increasingly recognized as safe in stable heart failure and provides specific benefits for the skeletal muscle compartment that aerobic training alone does not.
- Nutrition. Adequate protein (often 1.0-1.2 g/kg/day in stable HF) and avoidance of severe restrictions help. Cachectic patients should be referred to a cardiology dietitian.
- Treat anemia, thyroid disease, depression, and sleep apnea. All four are common in heart failure and all worsen muscle wasting.
Drug-level myostatin blockade is not part of standard care in 2026. The biology suggests it might be useful in select cachectic heart-failure patients, but the cardiac safety signal is not clean enough for the field to act on yet.
What is being researched
The active angles in 2026:
- Whether selective latent-myostatin antibodies (like apitegromab) have a different cardiac safety profile than ActRIIB-Fc traps and could be tested in cardiac cachexia
- Whether AT1 receptor blockers (an existing heart-failure class) reduce myostatin signaling enough to explain part of their muscle-preserving effect
- Whether SGLT2 inhibitors, now standard in both HFrEF and HFpEF, indirectly reduce myostatin elevation by improving metabolic stress
- Whether sotatercept's success in pulmonary arterial hypertension translates to right-heart-failure indications without crossing into skeletal-muscle dosing
- Whether the GLP-1 obesity programs producing meaningful cardiovascular outcome data (SELECT, STEP-HFpEF) will inform a cardiac myostatin story
The next two years will likely sharpen this picture as the obesity-class data matures.
Sources
- Evaluation of Serum Myostatin Concentration in Chronic Heart Failure, PMC 2024
- Circulation Research, "Myostatin Regulates Energy Homeostasis in the Heart and Prevents Heart Failure"
- Biomolecules MDPI, "Myostatin and the Heart" 2023
- Journal of Physiology, "Myostatin from the heart: local and systemic actions in cardiac failure"
- European Journal of Heart Failure, "Myostatin: An Overlooked Player in Heart Failure?"
- Predictive value of serum myostatin for severity of clinical outcomes, EJIM 2019
- JACC, myostatin inhibition after experimental heart failure improves cardiac function
Frequently Asked Questions
Why is myostatin elevated in heart failure?
Two main reasons stack. The failing heart muscle itself starts to secrete myostatin under pathological stress, and skeletal muscle continues producing it in response to systemic inflammation and inactivity. The net effect is elevated circulating myostatin that drives muscle wasting in the legs, arms, and respiratory muscles — contributing to the cardiac cachexia syndrome.
Is there a myostatin inhibitor for heart failure?
No drug specifically targeting myostatin is approved for heart failure. Sotatercept (Winrevair) is approved for pulmonary arterial hypertension and traps activin A and GDF-11, but it is dosed too low for skeletal muscle effects and is not a heart-failure drug. Other myostatin-class drugs (bimagrumab, taldefgrobep alfa) are being developed for obesity-related muscle preservation, not for HF.
Would blocking myostatin help cardiac cachexia?
The biological logic is appealing — lower myostatin should slow muscle protein breakdown. The practical concern is cardiac safety: animal data suggests myostatin restrains pathological cardiac hypertrophy, so eliminating it entirely could destabilize a failing heart. No large clinical trial has yet tested this in cardiac cachexia.
Does cardiac rehab lower myostatin?
Yes, in the skeletal muscle compartment. Structured aerobic and resistance training during cardiac rehab reduces muscle myostatin expression, raises lean mass, and improves functional capacity in stable heart failure. The cardiac-muscle myostatin signal is harder to influence with exercise alone, but the systemic and skeletal-muscle benefit is well-documented.
Is sotatercept used for heart failure?
Not for heart failure directly. It is approved for pulmonary arterial hypertension (a disease of small lung arteries that secondarily causes right-heart strain). The CADENCE trial in 2026 showed improvements in pulmonary vascular resistance in HFpEF patients with combined post- and pre-capillary pulmonary hypertension, but a formal HF approval has not happened. See the sotatercept article for the full clinical record.
What can a heart failure patient do to protect muscle?
Stay on guideline-directed medical therapy at maximum tolerated doses, complete a cardiac rehab program if eligible, train resistance and aerobic capacity within tolerance, eat 1.0-1.2 g/kg/day of protein unless contraindicated, treat anemia and sleep apnea, and avoid bed rest beyond what is clinically necessary. Discuss any supplement or peptide use with the cardiology team because of interaction risk.
This article is for educational purposes only and is not medical advice. Heart failure is a serious cardiac condition that requires care from a board-certified cardiologist, ideally one with heart-failure expertise. Do not adjust medications, start exercise, or pursue any myostatin-targeted therapy without explicit discussion with your heart-failure team. Cachexia in heart failure benefits from specialized cardiology dietitian input and structured cardiac rehabilitation programs.
